Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study probes hidden effects of shock drugs on tiny vessels

NCT ID NCT07312071

Knowledge-focused Sponsor: Gaziosmanpasa Research and Education Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 30 patients with septic shock in the ICU. Researchers wanted to see how high doses of the drug norepinephrine affect not just large blood vessels, but also tiny ones (microcirculation). They used a non-invasive light-based device to measure oxygen levels in arm tissue during a brief blood flow stop-and-release test. The goal was to understand if these microcirculation measurements relate to standard blood oxygen readings and could guide better treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
norepinephrine (vasopressor)
What this could lead to
If successful, this could help doctors better understand how to monitor and treat septic shock by looking at both large and small blood vessels, potentially improving patient outcomes.
What could go wrong
This is a small, completed study with only 30 participants, so results may not apply to all patients. It focuses on understanding, not a new treatment, so direct benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Apr 2023

Finished

Sep 2023

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Diagnosis of septic shock * Receiving vasopressor and mechanical ventilation therapy * Presence of a central venous catheter that allows ScvO₂ sampling * Ability to obtain tissue oxygenation (stO₂) measurements using a NIRS probe placed on the thenar eminence * Written informed consent obtained from patient or legal representative Exclusion Criteria: * Local infection, wound, or skin lesion at the planned NIRS probe application site * Mean arterial pressure (MAP) \< 60 mmHg despite vasopressor therapy * Pregnancy * Inability to safely perform the vascular occlusion test (as judged by treating clinician) * Any condition preventing safe blood sampling or reliable stO₂ measurement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemodynamic instability are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis ischemic disease Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodynamic instability Sepsis Septic shock Tissue ischemia

Contacts and locations

Locations

  • Gaziosmanpasa Training Research Hospital

    Istanbul, 34255, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.